D

Deciphera Pharmaceuticals Inc
F:D05

Watchlist Manager
Deciphera Pharmaceuticals Inc
F:D05
Watchlist
Price: 49.75 EUR 1.84%
Market Cap: 4.1B EUR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one D05 stock under the Base Case scenario is 13.29 EUR. Compared to the current market price of 49.75 EUR, Deciphera Pharmaceuticals Inc is Overvalued by 73%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

D05 Relative Value
Base Case
13.29 EUR
Overvaluation 73%
Relative Value
Price
D
Worst Case
Base Case
Best Case

Valuation Multiples

27.3
P/S
P/S
Price to Sales
27.3
vs History
19
vs Industry
29
Median 3Y
9.2
Median 5Y
18.2
Industry
7.5
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-6.7
Median 5Y
-7
Industry
24.4
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-8.4
Median 5Y
-8.8
Industry
20.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-8.4
Median 5Y
-8.5
Industry
23
More Details
15.1
P/B
P/B
Price to Book Value
15.1
vs History
0
vs Industry
7
Median 3Y
3.8
Median 5Y
4
Industry
2.8
More Details
25.7
EV/S
EV/S
Enterprise Value to Sales
25.7
vs History
17
vs Industry
26
Median 3Y
6.2
Median 5Y
16.4
Industry
8
More Details
26.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
26.5
vs History
17
vs Industry
24
Median 3Y
6.5
Median 5Y
16.7
Industry
10.2
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-4.8
Median 5Y
-5.6
Industry
5
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-4.8
Median 5Y
-5.5
Industry
5
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-6.6
Median 5Y
-7.1
Industry
5.5
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-6.6
Median 5Y
-6.9
Industry
3.9
More Details
34.9
EV/IC
EV/IC
Enterprise Value to IC
34.9
vs History
1
vs Industry
9
Median 3Y
7.6
Median 5Y
12.4
Industry
5
More Details

Multiples Across Competitors

D05 Competitors Multiples
Deciphera Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Deciphera Pharmaceuticals Inc
F:D05
4.1B EUR 27.3 -25.1 -22 -21.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 976 556.8 -161 485.5 -196 095 -193 857.3
US
Abbvie Inc
NYSE:ABBV
348.5B USD 6.1 84.2 15.9 23.5
US
Amgen Inc
NASDAQ:AMGN
154B USD 4.4 23.3 18.3 18.3
US
Gilead Sciences Inc
NASDAQ:GILD
149.3B USD 5.2 25.2 10.8 14.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 073.5 -529.1 -576.1 -560.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
94.7B USD 8.3 26 19.1 20
AU
CSL Ltd
ASX:CSL
126.3B AUD 5.4 30 18.4 23
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
59.7B USD 4.2 13.4 12 13.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
56.1B USD 22.8 -176 -438.5 -301
US
Seagen Inc
F:SGT
39.3B EUR 20 -61.2 -66 -59.6
P/E Multiple
Earnings Growth PEG
US
D
Deciphera Pharmaceuticals Inc
F:D05
Average P/E: 33.7
Negative Multiple: -25.1 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 485.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
84.2
88%
1
US
Amgen Inc
NASDAQ:AMGN
23.3
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
25.2
189%
0.1
US
E
Epizyme Inc
F:EPE
Negative Multiple: -529.1 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26
N/A N/A
AU
CSL Ltd
ASX:CSL
30
16%
1.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.4
7%
1.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -176 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.2 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
D
Deciphera Pharmaceuticals Inc
F:D05
Average EV/EBITDA: 15.7
Negative Multiple: -22 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 095 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.9
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.3
10%
1.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.8
6%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -576.1 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
19.1
17%
1.1
AU
CSL Ltd
ASX:CSL
18.4
11%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12
11%
1.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -438.5 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -66 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
D
Deciphera Pharmaceuticals Inc
F:D05
Average EV/EBIT: 18.9
Negative Multiple: -21.8 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 857.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.5
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.3
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
14.9
11%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -560.8 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20
17%
1.2
AU
CSL Ltd
ASX:CSL
23
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.5
11%
1.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -301 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.6 N/A N/A

See Also

Summary
D05 intrinsic value, competitors valuation, and company profile.
DCF Valuation
D05 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
D05 stock valuation using valuation multiples.
Wall Street Estimates
D05 price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
D05 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 273,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.